National Asset Management Inc. Purchases 63 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

National Asset Management Inc. lifted its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 7.7% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 877 shares of the medical research company’s stock after acquiring an additional 63 shares during the quarter. National Asset Management Inc.’s holdings in Bio-Rad Laboratories were worth $453,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. Strs Ohio boosted its stake in Bio-Rad Laboratories by 121.9% in the 2nd quarter. Strs Ohio now owns 5,305 shares of the medical research company’s stock worth $2,395,000 after purchasing an additional 2,914 shares during the period. Nissay Asset Management Corp Japan ADV boosted its stake in Bio-Rad Laboratories by 11.6% in the 2nd quarter. Nissay Asset Management Corp Japan ADV now owns 2,344 shares of the medical research company’s stock worth $1,058,000 after purchasing an additional 244 shares during the period. DekaBank Deutsche Girozentrale boosted its stake in Bio-Rad Laboratories by 5.1% in the 3rd quarter. DekaBank Deutsche Girozentrale now owns 12,123 shares of the medical research company’s stock worth $6,142,000 after purchasing an additional 587 shares during the period. Nordea Investment Management AB boosted its stake in Bio-Rad Laboratories by 134.2% in the 2nd quarter. Nordea Investment Management AB now owns 2,300 shares of the medical research company’s stock worth $1,008,000 after purchasing an additional 1,318 shares during the period. Finally, Envestnet Asset Management Inc. boosted its stake in Bio-Rad Laboratories by 2.5% in the 3rd quarter. Envestnet Asset Management Inc. now owns 43,905 shares of the medical research company’s stock worth $22,631,000 after purchasing an additional 1,072 shares during the period. Institutional investors own 60.06% of the company’s stock.

Shares of NYSE BIO opened at $569.98 on Friday. The stock has a market cap of $17.00 billion, a price-to-earnings ratio of 4.88 and a beta of 1.00. Bio-Rad Laboratories, Inc. has a 1-year low of $309.38 and a 1-year high of $648.39. The stock’s 50-day moving average is $574.77 and its 200 day moving average is $508.74.

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings data on Thursday, October 29th. The medical research company reported $3.00 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.85 by $1.15. The company had revenue of $647.26 million for the quarter, compared to analysts’ expectations of $567.35 million. Bio-Rad Laboratories had a return on equity of 3.77% and a net margin of 147.91%. Bio-Rad Laboratories’s revenue for the quarter was up 15.5% compared to the same quarter last year. During the same period last year, the firm posted $1.61 EPS. As a group, sell-side analysts anticipate that Bio-Rad Laboratories, Inc. will post 9.61 earnings per share for the current fiscal year.

Several research firms have weighed in on BIO. Citigroup raised their price target on Bio-Rad Laboratories from $525.00 to $625.00 and gave the company a “buy” rating in a report on Friday, July 31st. Jefferies Financial Group reaffirmed a “market perform” rating and issued a $666.00 price target on shares of Bio-Rad Laboratories in a report on Thursday, September 3rd. Smith Barney Citigroup raised their price target on Bio-Rad Laboratories from $625.00 to $675.00 in a report on Friday, October 30th. Finally, Wells Fargo & Company raised their price target on Bio-Rad Laboratories from $590.00 to $650.00 and gave the company an “overweight” rating in a report on Friday, October 30th.

In other Bio-Rad Laboratories news, EVP Annette Tumolo sold 1,200 shares of Bio-Rad Laboratories stock in a transaction that occurred on Friday, November 6th. The stock was sold at an average price of $640.72, for a total value of $768,864.00. Following the transaction, the executive vice president now directly owns 5,322 shares of the company’s stock, valued at approximately $3,409,911.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 27.50% of the stock is owned by insiders.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the United States, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components.

See Also: What is the Consumer Price Index (CPI)?

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.